INVO Bioscience, Inc. Stock price

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.13 USD +2.73% Intraday chart for INVO Bioscience, Inc. +2.73% -16.30%
Sales 2023 * 3.59M Sales 2024 * 14.84M Capitalization 2.82M
Net income 2023 * -9M Net income 2024 * -4M EV / Sales 2023 * 0.78 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.19 x
P/E ratio 2023 *
-0.19 x
P/E ratio 2024 *
-3.9 x
Employees 16
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.07%
More Fundamentals * Assessed data
Dynamic Chart
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024. CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024. CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024. CI
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc. CI
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal CI
Top Premarket Gainers MT
Earnings Flash (INVO) INVO BIOSCIENCE Reports Q3 Revenue $974,894 MT
INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks MT
Transcript : INVO Bioscience, Inc., NAYA Biosciences Inc. - Special Call
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Mixed in Monday Afternoon Trading MT
INVO Bioscience Shares Skyrocket After Signing Deal to Buy NAYA Biosciences MT
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth MT
NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. in a reverse merger transaction for $90.7 million. CI
More news
1 day+2.73%
1 week+2.73%
Current month-1.74%
1 month+3.65%
3 months-19.29%
6 months+32.15%
Current year-16.30%
More quotes
1 week
1.01
Extreme 1.01
1.19
1 month
1.00
Extreme 1
1.29
Current year
0.81
Extreme 0.81
1.35
1 year
0.50
Extreme 0.5
13.52
3 years
0.50
Extreme 0.5
112.60
5 years
0.50
Extreme 0.5
278.40
10 years
0.50
Extreme 0.5
953.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 17-10-10
Director of Finance/CFO 56 21-06-13
Chief Tech/Sci/R&D Officer - 20-02-12
Members of the board TitleAgeSince
Director/Board Member 56 19-12-15
Director/Board Member 64 20-09-13
Corporate Secretary 55 08-09-30
More insiders
Date Price Change Volume
24-03-28 1.13 +2.73% 14,363
24-03-27 1.1 +8.91% 18,562
24-03-26 1.01 -11.40% 16,615
24-03-25 1.14 +0.88% 40,099
24-03-22 1.13 +2.73% 8,875

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. It operates three INVO Centers in North America.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.13
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock INVO Bioscience, Inc. - Nasdaq